U.S.A. v. Batke

Citation Codes

Equivalent Citations

citation codes

Docket Number

0980 2:22CR00094-TOR-1

Acts

Food And Drugs — Drug Abuse Prevention And Control — Control And Enforcement — Introductory Provisions — Definitions

See more information ...

Smart Summary

Factual and Procedural Background

Defendant Brandon Christopher Batke was placed under pretrial release supervision by U.S. Magistrate Judge James A. Goeke on September 1, 2022, subject to standard conditions including prohibition on unlawful use or possession of narcotics and controlled substances. On October 6, 2022, Batke confirmed his understanding of these conditions. On December 12, 2022, Batke submitted a urine specimen during a random drug test, which later tested positive for norfentanyl, a metabolite of fentanyl. The specimen tested negative for fentanyl itself. Batke denied ingesting fentanyl. Following the positive test result, pretrial services increased his drug testing requirements. A petition for action on the conditions of pretrial release was filed, and the court ultimately ordered no action at this time.

Legal Issues Presented

Whether the defendant violated the conditions of pretrial release by testing positive for norfentanyl.
Whether any action should be taken by the court in response to the alleged violation.

Arguments of the Parties

Pretrial Services Officer's Arguments

Defendant tested positive for norfentanyl, indicating a violation of the pretrial release condition prohibiting use or possession of controlled substances.
Despite the positive test, the defendant denies ingesting fentanyl.
In response to the positive test, drug testing requirements for the defendant have been increased.
Petition requests that the court take no action at this time.

Defendant's Position

Defendant adamantly denies ingesting fentanyl.

Table of Precedents Cited

No precedents were cited in the provided opinion.

Court's Reasoning and Analysis

The court considered the report of the pretrial services officer detailing the positive test for norfentanyl and the defendant's denial of fentanyl ingestion. Despite the alleged violation, the court elected to take no action at this time, indicating a measured approach that acknowledges the positive test but also the defendant's denial and possibly the negative fentanyl result. The court’s decision reflects discretion in weighing the evidence and the circumstances surrounding the alleged violation.

Holding and Implications

Holding: The court ordered No Action in response to the petition for action on conditions of pretrial release.

Implications: The defendant remains under pretrial release supervision without modification of conditions or issuance of warrants or summons. No new precedent was established, and the decision directly affects only the parties by maintaining the status quo regarding the defendant’s supervision conditions.

Show full summary ...

U.S.A. v. Batke, Brandon Christopher

PETITION FOR ACTION ON CONDITIONS OF PRETRIAL RELEASE

COMES NOW Erik Carlson, PRETRIAL SERVICES OFFICER presenting an official report upon the conduct of defendant Brandon Christopher Batke, who was placed under pretrial release supervision by the Honorable U.S. Magistrate Judge James A. Goeke, sitting in the Court at Spokane, Washington, on the 1^st day of September 2022, under the following conditions:

Standard Condition #10: Defendant shall refrain from the use or unlawful possession of a narcotic drug or other controlled substances defined in 21 U.S.C. § 802, unless prescribed by a licensed medical practitioner in conformance with Federal law. Defendant may not use or possess marijuana, regardless of whether Defendant has been authorized medical marijuana under state law.

RESPECTFULLY PRESENTING PETITION FOR ACTION OF COURT FOR CAUSE AS FOLLOWS:

On October 6, 2022, the undersigned officer reviewed the conditions of pretrial release supervision with Mr. Batke. Mr. Batke acknowledged an understanding of the release conditions at that time.

Violation #1: Brandon Christopher Batke is alleged to have violated the conditions of pretrial release supervision by testing positive for the presence of norfentanyl on December 12, 2022.

On December 12, 2022, Mr. Batke submitted to a random urinalysis at his outpatient substance abuse treatment provider, Spokane Addiction and Recovery Center (SPARC). Subsequently, the urine specimen was sent to Cordant Health Solutions (Cordant).

On January 10, 2023, Cordant confirmed the aforementioned urine specimen tested positive for norfentanyl. Norfentanyl is a metabolite of fentanyl. It should be noted, the urine specimen tested negative for fentanyl.

The undersigned officer has had multiple discussions regarding the above-noted test result. Mr. Batke has adamantly denied ingesting fentanyl. In response to the aforementioned positive drug test, the undersigned officer has increased Mr. Batke's drug testing expectations through the U.S. Probation Office.

PRAYING THAT THE COURT WILL ORDER NO ACTION AT THIS TIME

I declare under the penalty of perjury that the foregoing is true and correct.

Erik Carlson U.S. Pretrial Services Officer

THE COURT ORDERS

[ X] No Action

[ ] The Issuance of a Warrant

[ ] The Issuance of a Summons

[ ] The incorporation of the violation(s) contained in this petition with the other violations pending before the Court.

[ ] Defendant to appear before the Judge assigned to the case.

[ ] Defendant to appear before the Magistrate Judge.

[ ] Other